NCT00372060View on ClinicalTrials.gov

MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)

PHASE3CompletedINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

August 21, 2006

Primary Completion Date

February 5, 2008

Study Completion Date

February 5, 2008

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

sitagliptin phosphate

Sitagliptin (MK0431) 50 or 100 mg once daily for 52 weeks

DRUG

Comparator: sitagliptin phosphate (MK0431)

Sitagliptin (MK0431) 50 or 100 mg once daily for 40 weeks

DRUG

Comparator: pioglitazone

pioglitazone once daily for 52 weeks

DRUG

Comparator: placebo (unspecified)

Placebo once daily for 12 weeks

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00372060 - MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED) | Biotech Hunter | Biotech Hunter